Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All studies

Vorasidenib

INDIGO

Servier · Phase 3 · Active, not recruiting · Enrollment 331

NCT04164901

Catalyst Primary completion. 09.06.2022. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmPopulationDoseEstimandComparatorEfficacy
Vorasidenib 40 mg dailygrade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery only (n = 168 vs 163)40 mgITTplaceboPFS hazard ratio vs placebo (BIRC): 0.39 HR, primary analysistime to next intervention hazard ratio: 0.26 HR, primary analysismedian time to next intervention, placebo: 17.8 months, primary analysismedian PFS, vorasidenib: 27.7 months, NEJM 2023median PFS, placebo: 11.1 months, NEJM 2023median PFS, extended follow-up: 44.1 months, ASCO 2026, preliminaryobjective response rate, extended follow-up: 20.8%, ASCO 2026, preliminary